Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective
Although sotagliflozin increases pharmacy costs for recently hospitalized HF patients with T2D, approximately 21%-68% of pharmacy costs were offset from reduced rehospitalization and ED visits.
Authors
- Slaven Sikirica
- Jason T. Shafrin (ORCID: https://orcid.org/0000-0001-8444-5979)
- Shanshan Wang (ORCID: https://orcid.org/0009-0007-3503-0161)
- Jae‐Hong Kim (ORCID: https://orcid.org/0000-0002-8019-0208)
Institutions
- Lexicon Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-03-28
- DOI
- https://doi.org/10.18553/jmcp.2025.31.4.386
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29